Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times

被引：0
|
作者：
Ashwell, SG
Home, PD
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A118 / A118
页数：1
相关论文
共 50 条
  • [31] EVALUATION OF ONCE-DAILY ADMINISTRATION OF INSULIN GLARGINE IN DOGS WITH NATURALLY OCCURING DIABETES MELLITUS
    Kim, A. Y.
    Cho, K.
    Noh, S.
    Paek, J.
    Lee, M.
    Chang, D.
    Yang, M. P.
    Kang, J. H.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2012, 26 (03) : 757 - 757
  • [32] Randomised open-label trial of insulin lispro protamin suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients
    Giugliano, D.
    Cleall, S.
    Pontiroli, A. E.
    Koivisto, V.
    DIABETOLOGIA, 2011, 54 : S421 - S422
  • [33] Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes
    Derosa, G.
    Franzetti, I.
    Querci, F.
    Romano, D.
    D'Angelo, A.
    Maffioli, P.
    DIABETES OBESITY & METABOLISM, 2015, 17 (06): : 554 - 559
  • [34] Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal-Bolus Insulin: Phase 4 OPTIMIZE Study
    Mathieu, Chantal
    Weisnagel, S. John
    Stella, Peter
    Bruhwyler, Jacques
    Alexandre, Kathy
    DIABETES THERAPY, 2020, 11 (02) : 495 - 507
  • [35] Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine
    Bradley, C.
    Gilbride, C. J. B.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 50 - 65
  • [36] Treatment Satisfaction in Adults with Type 1 Diabetes Using Meal-time Inhaled Technosphere® Insulin (Afrezza®) in Combination with Insulin Glargine (Lantus®) Versus Insulin Lispro (Humalog®) in Combination with Glargine
    Petrucci, Richard E.
    Peyrot, Mark
    Rubin, Richard R.
    DIABETES, 2011, 60 : A257 - A257
  • [37] Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial (vol 371, pg 1073, 2008)
    Bretzel, R. G.
    Nuber, U.
    Landgraf, W.
    Owens, D. R.
    Bradley, C.
    Linn, T.
    LANCET, 2008, 372 (9640): : 718 - 718
  • [38] Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive people with type 2 diabetes: comparison with insulin glargine
    Cuddihy, R.
    Tack, C. J.
    Heise, T.
    Davidson, J.
    Gouet, D.
    Liebl, A.
    Romero, E.
    Mersebach, H.
    Dykiel, P.
    Jorde, R.
    DIABETOLOGIA, 2010, 53
  • [39] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    Aroda, Vanita
    Bain, Stephen
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Bergan, Eirik Quamme
    Zacho, Jeppe
    Devries, J. Hans
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [40] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with Type 2 diabetes (SUSTAIN 4)
    Aroda, V. R.
    Bain, S. C.
    Cariou, B.
    Piletic, M.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    de Vries, J. H.
    DIABETIC MEDICINE, 2017, 34 : 146 - 146
12345